Posts

Showing posts from February, 2014

The Italian Competition Authority opens a monitoring procedure against the parties to a merger insurance

By Article 19 of the Italian Competition Act n. 287/1990 the Italian Competition Authority (ICA) is empowered to open a monitoring procedure against the parties to a merger that has been conditionally cleared to verify the parties’ compliance with the obligations imposed on them in the authorization decision. If the ICA establishes that the parties breached those obligations, it has to fine them. Indeed, according to the case law developed in the application of Article 19 failure in correctly implementing the remedies in conditional clearance decisions has been equated to implement a prohibited merger. With a decision made on 19 June 2012 the (ICA) conditionally cleared the Unipol acquisition of Premafin (case C11524 Unipol/Fonsai ). In order to deal with the competition problems that the proposed transaction would create in many insurance markets, the ICA imposed on Unipol the obligation to sell a number of assets. And In January 2013 the ICA extended the deadline by which Unipol ...

The Italian Competition Authority fines EasyJet and Ryanair for unfair commercial practices

By a recent decision the Italian Competition Authority (ICA) has found that the on-line systems for purchase of air tickets of EasyJet ( Case PS7488 ) and Ryanair ( Case PS7245 ) to be in breach of the unfair commercial practices provisions in the Italian Consumer Code. In particular, the ICA reproached the airlines to have given inadequate or misleading information with regard to travel insurance policies they offered to consumers during the on–line process for the booking of tickets. As a result, consumers were unable to take a fully informed decision on whether take out the offered policy or not. The ICA imposed a € 850,000.00 fine on Ryanair and a € 200,000.00 fine on EasyJet, considering the changes the latter made to the information supplied to consumers in the on-line booking system when the ICA investigations were still pending. The press release of the ICA is available at    http://www.agcm.it/trasp-statistiche/doc_download/4090-press-release-english-version....

The Italian Competition Authority to investigate into a cartel for the supply of tumour drugs to some regional health agencies

The Italian Competition Authority (ICA) will investigate into bid rigging practices allegedly carried out by Novartis Farma and Italfarmaco with regard to the competitive procedures organized by some regional health authorities for the supply of a tumour drug ( CaseI770 Octreotid Supplies ). The ICA decided to open an Article 101 TFEU investigation against Novartis Farma and Italfarmaco upon the receipt of complaint filed by the Arca, the purchase centre in charge for the purchase of drugs on behalf of the health authorities of Lombardy. Arca reported that Novartis Farma and Italfarmaco appeared to have coordinated their conducts with regard to competitive tender procedures to select the supplier of the active substance of octreotid, which is used in drugs for the treatment of tumours, tendered over the 2010-2013 period. The ICA pointed out that Novartis Farma and Italfarmaco were the only manufactures of drugs incorporating octreotid and marketed with the same dosages Arca inten...

Patent Law v Competition Law: the Italian highest administrative delivers judgment on the Pfizer Xalatan case in favour of the Italian Competition Authority

By a judgment made on 14 January 2014 the Italian Council of State (CoS) delivers the appeal on the Pfizer Xalatan case ( Case n. 116/2014 ) finding in favour of the appellant, the Italian Competition Authority (ICA). The ICA had previously found Pfizer to have abused its dominant position in the market for glaucoma medicines based on latanaprost when it deliberately misused the patent application procedures with the aim to prolong the patent protection for Xalatan ( Case A431 ). More precisely, Pfizer relied on a patent divisional application to obtain a supplementary protection certificate, thereby extending the length of patent protection for its patented drug. In the ICA view, Pfizer  acted in this way with the intent to foreclose the market entry of generics when the patent term for Xalaton in Italy was due to expire soon. Therefore, the ICA imposed on Pfizer a fine of €10,6 million. The ICA decision was much debated within the competition law community and different views ...

An alleged cartel in the concrete market to be investigated by the Italian Competition Authority

By a decision made on 22 January 2014 ( Case I772 ) the Italian Competition Authority (ICA) has opened an Article 102 TFEU investigation against 11 firms alleged to have put into practice a cartel in the markets for the production and commercialization of concrete in the north-east of Italy.   The ICA feared that the parties had cartelized the concrete market at least in the north-eastern provinces of Udine and Trieste by allocating clients and fixing prices in order to crystallize their market shares. To this end, the parties organized several and frequent meetings between their representatives and a system for the exchange of information through a third party, a consultancy firm. In this way the parties exchanged commercially sensitive data regarding the supplies of concrete to their respective customers. The ICA pointed out that the availability of such data was instrumental in monitoring the parties’ compliance with the agreement and necessary to a retaliatory mechanism tha...